CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调控细胞转运：解决 CAR-T 与 NK 细胞治疗实体瘤中的失败问题
英文原题：Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours.
查看英文原题
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
内源性或过继转移淋巴细胞向实体瘤块的精准引导对于实现最佳抗肿瘤效果和改善患者安全性是必需的。当抗肿瘤淋巴细胞靠近恶性细胞时，最能实现肿瘤的识别和清除。例如，可溶性因子、细胞毒性颗粒的区域性分泌以及细胞表面分子相互作用是肿瘤细胞死亡和抑制新生血管形成、肿瘤相关抑制细胞或基质细胞所必需的。单个肿瘤细胞克隆对细胞治疗的耐药性以及实体瘤的敌对环境是过继细胞治疗的主要挑战。我们综述了可能有助于克服免疫细胞向肿瘤细胞块迁移不足的策略。我们认为，现有的“竞争性”方法现在应被重新审视，作为改善CAR-T 和NK细胞治疗的补充方法。
展开英文摘要原文
The precision guiding of endogenous or adoptively transferred lymphocytes to the solid tumour mass is obligatory for optimal anti-tumour effects and will improve patient safety. The recognition and elimination of the tumour is best achieved when anti-tumour lymphocytes are proximal to the malignant cells.
For example, the regional secretion of soluble factors, cytotoxic granules, and cell-surface molecule interactions are required for the death of tumour cells and the suppression of neovasculature formation, tumour-associated suppressor, or stromal cells. The resistance of individual tumour cell clones to cellular therapy and the hostile environment of the solid tumours is a major challenge to adoptive cell therapy.
We review the strategies that could be useful to overcoming insufficient immune cell migration to the tumour cell mass.
We argue that existing 'competitive' approaches should now be revisited as complementary approaches to improve CAR T and NK cell therapy.
论文信息
- 作者
- White LG、Goy HE、Rose AJ、McLellan AD
- 单位
- Department of Microbiology and Immunology, University of Otago, Dunedin 9016, New Zealand.
- 文献类型
- 综述
- 期刊
- Cancers2022 Feb 15
- 原文标识
- PubMed 35205725 · DOI 10.3390/cancers14040978
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →